Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in China, announced that its HT Supreme drug-eluting stent system has been included in the reimbursement drug list (RDL) in France, effective as of October 4, 2023. This inclusion marks a significant milestone for the company’s efforts to expand patient access to its innovative cardiovascular products.
Product Development and Approvals
The HT Supreme drug-eluting stent system is developed based on Sino Med’s proprietary “Healing window stage” theory, which aims to optimize the healing process post-implantation. The product has already obtained marketing approvals in the European Union (EU), China, Thailand, Singapore, Indonesia, and Turkey, highlighting its broad acceptance and compliance with international medical standards.
Impact of Reimbursement Inclusion
The inclusion of the HT Supreme stent system in France’s RDL is expected to increase patient access and affordability, as reimbursement can significantly reduce the financial burden on patients requiring such medical interventions. This development not only benefits French patients but also strengthens Sino Medical Sciences Technology Inc.’s position in the global medical device market.
Conclusion
The addition of Sino Medical Sciences Technology Inc.’s HT Supreme drug-eluting stent system to the RDL in France underscores the company’s commitment to improving cardiovascular health outcomes and making its advanced medical products more accessible to patients worldwide.-Fineline Info & Tech
